Terms: = Ovarian cancer AND OMD, osteoadherin, 4958, ENSG00000127083, Q99983, SLRR2C
5 results:
1. Strategies for reducing ovarian dose in volumetric modulated arc therapy (VMAT) for postoperative uterine cervical cancer.
Yoshihiro U; Shingo O; Masaru I; Masayoshi M; Koji K; Shoji K; Iori S; Kazuhiko O; Teruki T
Br J Radiol; 2018 Jan; 91(1081):20160777. PubMed ID: 29072492
[TBL] [Abstract] [Full Text] [Related]
2. Pathologic Risk Factors for Metastatic Disease in Postpubertal Patients With Clinical Stage I Testicular Stromal Tumors.
Rove KO; Maroni PD; Cost CR; Fairclough DL; Giannarini G; Harris AK; Schultz KA; Cost NG
Urology; 2016 Nov; 97():138-144. PubMed ID: 27538802
[TBL] [Abstract] [Full Text] [Related]
3. Pathologic Risk Factors in Pediatric and Adolescent Patients With Clinical Stage I Testicular Stromal Tumors.
Rove KO; Maroni PD; Cost CR; Fairclough DL; Giannarini G; Harris AK; Schultz KA; Cost NG
J Pediatr Hematol Oncol; 2015 Nov; 37(8):e441-6. PubMed ID: 26479987
[TBL] [Abstract] [Full Text] [Related]
4. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy.
Rodriguez N; Rauh-Hain JA; Shoni M; Berkowitz RS; Muto MG; Feltmate C; Schorge JO; Del Carmen MG; Matulonis UA; Horowitz NS
Gynecol Oncol; 2012 May; 125(2):362-6. PubMed ID: 22333992
[TBL] [Abstract] [Full Text] [Related]
5. Common malignancy-associated regions of transcriptional activation (MARTA) in human prostate, breast, ovarian, and colon cancers are targets for DNA amplification.
Glinsky GV; Ivanova YA; Glinskii AB
Cancer Lett; 2003 Nov; 201(1):67-77. PubMed ID: 14580688
[TBL] [Abstract] [Full Text] [Related]
